Galapagos: Triple combination advances, positive read-across (LLY/ROG)

BUY, Fair Value EUR52 (+30%)
News published on October Thursday 15, 2015
Share on

GLPG’s development for its triple combo advances well with the nomination of a second corrector for pre-clinical studies. The companies also identified other 2nd generation corrector series which might fuel the company’s CF pipeline in the upcoming months. We see two positive read-acrosses from (i) LLY’s JAK-inhibitor, baricitinib, which topped Humira in a phase III study and (ii) Roche’s BD activities in the auto-immune field with a promising early-stage pipeline which should not however allow the Pharma to fill its late stage pipeline with two blockbusters coming off-patent in 2018 and 2019.

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities